Evidence map›Paper›PMID 37326901›Full record

ReviewAdvances in therapy2023

The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of Type 2 Diabetes: A Narrative Review.

Hanna Kwiendacz, Katarzyna Nabrdalik, Leszek Czupryniak, Tomasz Klupa, Maciej Małecki, Małgorzata Myśliwiec, Krzysztof Strojek, Janusz Gumprecht

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Safety and Effectiveness of Concomitant iGlarLixi and SGLT-2i Use in People with T2D During Ramadan Fasting: A SoliRam Study Sub-analysis.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Hanna KwiendaczDepartment of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, 3 Maja Str. 41-800, Zabrze, Poland. hkwiendacz@sum.edu.pl.ORCID http://orcid.org/0000-0002-1256-0414
Katarzyna NabrdalikDepartment of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, 3 Maja Str. 41-800, Zabrze, Poland.
Leszek CzupryniakDiabetology and Internal Medicine Department, Warsaw Medical University, Warsaw, Poland.
Tomasz KlupaDepartment of Metabolic Diseases, Jagiellonian University Medical College, Kraków, Poland.
Maciej MałeckiDepartment of Metabolic Diseases, Jagiellonian University Medical College, Kraków, Poland.
Małgorzata MyśliwiecDepartment of Pediatrics, Diabetology and Endocrinology, Medical University of Gdansk, Gdańsk, Poland.
Krzysztof StrojekDepartment of Internal Diseases, Diabetology and Cardiometabolic Diseases, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
Janusz GumprechtDepartment of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, 3 Maja Str. 41-800, Zabrze, Poland.
Medical University of Silesia · PLJagiellonian University · PLGdańsk Medical University · PLMedical University of Warsaw · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

iGlarLixi is a fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide used in the treatment of type 2 diabetes. iGlarLixi has proven clinical benefits in terms of glycemia, weight control, and safety, defined by the risk of hypoglycemia. It simultaneously targets many pathophysiologic abnormalities which are at the root of type 2 diabetes and thus presents a complementary mode of action. Finally, it may also address diabetes treatment burden, and, by decreasing the complexity of treatment, it may improve patient adherence and persistence and fight against clinical inertia. This article reviews the results of major randomized controlled trials in people with type 2 diabetes that compared iGlarLixi to other therapeutic regimens, representing different intensification strategies, such as basal supported oral therapy, oral antidiabetic drugs, and a combination of the latter with glucagon-like peptide 1 receptor agonists. Moreover, as a supplement to randomized trials, data from real-world evidence have also been included.

Indexed as

Diabetes Mellitus, Type 2Blood GlucoseDrug CombinationsGlycated HemoglobinHumansHypoglycemic AgentsInsulin GlargineBlood GlucoseDrug CombinationsGlycated HemoglobinHypoglycemic AgentsInsulin GlargineDiabetes mellitusFixed-ratio combinationInsulin glargineLixiLan-GLixiLan-LLixiLan-OLixisenatideSoliMix

Identifiers

PMID37326901
PMCPMC10329951
OpenAlexW4380872092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.